ALPHAMAB ONCOLO.DL-000002 Asset Resilience Ratio
ALPHAMAB ONCOLO.DL-000002 asset resilience ratio. ALPHAMAB ONCOLO.DL-000002 (3NK) has an Asset Resilience Ratio of 52.05% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ALPHAMAB ONCOLO.DL-000002 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ALPHAMAB ONCOLO.DL-000002 (2021–2025)
Asset resilience ratio of ALPHAMAB ONCOLO.DL-000002 from 2021 to 2025. This chart shows how ALPHAMAB ONCOLO.DL-000002's Asset Resilience Ratio has changed over time. Read 3NK current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ALPHAMAB ONCOLO.DL-000002's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is ALPHAMAB ONCOLO.DL-000002's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.09 Billion | 52.05% |
| Total Liquid Assets | €1.09 Billion | 52.05% |
Asset Resilience Insights
- Very High Liquidity: ALPHAMAB ONCOLO.DL-000002 maintains exceptional liquid asset reserves at 52.05% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ALPHAMAB ONCOLO.DL-000002 Industry Peers by Asset Resilience Ratio
Compare ALPHAMAB ONCOLO.DL-000002's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
ALPHAMAB ONCOLO.DL-000002 Asset Resilience Ratio by Year (2021–2025)
ALPHAMAB ONCOLO.DL-000002 asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for ALPHAMAB ONCOLO.DL-000002.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 52.05% | €1.09 Billion ≈ $1.28 Billion |
€2.10 Billion ≈ $2.45 Billion |
+31.56pp |
| 2024-12-31 | 20.49% | €459.35 Million ≈ $537.02 Million |
€2.24 Billion ≈ $2.62 Billion |
+5.46pp |
| 2023-12-31 | 15.03% | €321.25 Million ≈ $375.57 Million |
€2.14 Billion ≈ $2.50 Billion |
+1.75pp |
| 2022-12-31 | 13.28% | €281.19 Million ≈ $328.74 Million |
€2.12 Billion ≈ $2.48 Billion |
-30.42pp |
| 2021-12-31 | 43.70% | €1.18 Billion ≈ $1.38 Billion |
€2.71 Billion ≈ $3.16 Billion |
-- |
About ALPHAMAB ONCOLO.DL-000002
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under th… Read more